Melissa McAlonis-Downes

Author PubWeight™ 16.91^‹?›

Rank	Title	Journal	Year	PubWeight™‹?›
1	Antisense oligonucleotide therapy for neurodegenerative disease.	J Clin Invest	2006	3.00
2	Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration.	Proc Natl Acad Sci U S A	2013	2.95
3	Elevated PGC-1α activity sustains mitochondrial biogenesis and muscle function without extending survival in a mouse model of inherited ALS.	Cell Metab	2012	1.92
4	Mutant SOD1 in cell types other than motor neurons and oligodendrocytes accelerates onset of disease in ALS mice.	Proc Natl Acad Sci U S A	2008	1.84
5	Enhancing mitochondrial calcium buffering capacity reduces aggregation of misfolded SOD1 and motor neuron cell death without extending survival in mouse models of inherited amyotrophic lateral sclerosis.	J Neurosci	2013	1.51
6	ALS-linked TDP-43 mutations produce aberrant RNA splicing and adult-onset motor neuron disease without aggregation or loss of nuclear TDP-43.	Proc Natl Acad Sci U S A	2013	1.48
7	Schwann cells expressing dismutase active mutant SOD1 unexpectedly slow disease progression in ALS mice.	Proc Natl Acad Sci U S A	2009	1.33
8	C1q induction and global complement pathway activation do not contribute to ALS toxicity in mutant SOD1 mice.	Proc Natl Acad Sci U S A	2013	1.17
9	Misfolded SOD1 associated with motor neuron mitochondria alters mitochondrial shape and distribution prior to clinical onset.	PLoS One	2011	1.07
10	Progressive spinal axonal degeneration and slowness in ALS2-deficient mice.	Ann Neurol	2006	1.04